Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Aumakhan, Bulbulgul ^a   Gaydos, Charlotte A ^b   Quinn, Thomas C ^b,c   Beyrer, Chris ^a   Benning, Lorie ^a   Minkoff, Howard ^d   Merenstein, Daniel J ^e   Cohen, Mardge ^f   Greenblatt, Ruth ^g   Nowicki, Marek ^h   Anastos, Kathryn ⁱ   Gange, Stephen J ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d MAIMONIDES MEDICAL CENTER   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f Department of Emergency Medicine   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA; BIOLOGICAL MARKER;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL LOSS; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ETHNIC DIFFERENCE; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MIXED INFECTION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; BLOOD; GENITAL HERPES; LONGITUDINAL STUDY; PHYSIOLOGY; VIRUS ACTIVATION;

HUMAN HERPESVIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS;

ADULT; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; RNA, VIRAL; VIRUS ACTIVATION;

EID: 77956332703     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009973     Document Type: Article

References (33)

1. Ashley RL, Wald A (1999) Genital herpes: Review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev 12(1): 1-8.
2. Chretien F, Belec L, Wingerstmann L, de Truchis P, Baudrimont M, et al. (1997) Central nervous system infection due to herpes simplex virus in AIDS. Arch Anat Cytol Pathol 45(2-3): 153-158.
3. Haanpaa M, Paavonen J (2004) Transient urinary retention and chronic neuropathic pain associated with genital herpes simplex virus infection. Acta Obstet Gynecol Scand 83(10): 946-949.
4. Tran TH, Stanescu D, Caspers-Velu L, Rozenberg F, Liesnard C, et al. (2004) Clinical characteristics of acute HSV-2 retinal necrosis. Am J Ophthalmol 137(5): 872-879.
5. Van de Perre P, Segondy M, Foulongne V, Ouedraogo A, Konate I, et al. (2008) Herpes simplex virus and HIV-1: Deciphering viral synergy. Lancet Infect Dis 8(8): 490-497.
6. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, et al. (2008) Effect of herpes simplex suppression on incidence of HIV among women in tanzania. N Engl J Med 358(15): 1560-1571.
7. Celum C, Wald A, Hughes J, Sanchez J, Reid S, et al. (2008) Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: A randomised, double-blind, placebo-controlled trial. Lancet 371(9630): 2109-2119.
8. Cowan FM, Pascoe SJ, Barlow KL, Langhaug LF, Jaffar S, et al. (2008) A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among zimbabwean sex workers. Sex Transm Infect 84(7): 548-553.
9. Cheng RG, Nixon DF (2009) Herpes simplex virus and HIV-1: Deciphering viral synergy. Lancet Infect Dis 9(2): 74; author reply74-5.
10. Greenblatt RM, Bacchetti P, Barkan S, Augenbraun M, Silver S, et al. (1999) Lower genital tract infections among HIV-infected and high-risk uninfected women: Findings of the women's interagency HIV study (WIHS). Sex Transm Dis 26(3): 143-151.
11. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, et al. (1998) The women's interagency HIV study. WIHS collaborative study group. Epidemiology 9(2): 117-125.
12. Ashley RL, Wu L, Pickering JW, Tu MC, Schnorenberg L (1998) Premarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for herpes simplex virus type-specific antibodies. J Clin Microbiol 36(1): 294-295.
13. Ameli N, Bacchetti P, Morrow RA, Hessol NA, Wilkin T, et al. (2006) Herpes simplex virus infection in women in the WIHS: Epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS 20(7): 1051-1058.
14. Ashley R, Cent A, Maggs V, Nahmias A, Corey L (1991) Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med 115(7): 520-526.
15. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L (1988) Comparison of western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 26(4): 662-667.
16. Spiegelman D, Hertzmark E (2005) Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 162(3): 199-200.
17. Koelle DM, Corey L (2008) Herpes simplex: Insights on pathogenesis and possible vaccines. Annu Rev Med 59: 381-395.
18. Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, et al. (1998) Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 101(7): 1500-1508.
19. Posavad CM, Koelle DM, Shaughnessy MF, Corey L (1997) Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proc Natl Acad Sci U S A 94(19): 10289-10294.
20. Harandi AM, Svennerholm B, Holmgren J, Eriksson K (2001) Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J Gen Virol 82(Pt 4): 845-853.
21. Milligan GN, Bernstein DI, Bourne N (1998) T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol 160(12): 6093-6100.
22. Zhu J, Hladik F, Woodward A, Klock A, Peng T, et al. (2009) Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 15(8): 886-892.
23. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, et al. (2010) Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 362(5): 427-439.
24. Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, et al. (2010) Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: A randomised placebo-controlled trial. Lancet.
25. Modjarrad K, Chamot E, Vermund SH (2008) Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 22(16): 2179-2185.
26. Lisco A, Vanpouille C, Margolis L (2009) A missed point in deciphering the viral synergy between herpes simplex virus and HIV. Lancet Infect Dis 9(9): 522-523.
27. Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, et al. (2008) Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: A randomized, placebocontrolled, cross-over trial. J Infect Dis 198(12): 1804-1808.
28. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, et al. (2007) Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 356(8): 790-799.
29. Delany-Moretlwe S, Lingappa JR, Celum C (2009) New insights on interactions between HIV-1 and HSV-2. Curr Infect Dis Rep 11(2): 135-142.
30. Dunne EF, Whitehead S, Sternberg M, Thepamnuay S, Leelawiwat W, et al. (2008) Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, chiang rai, thailand. J Acquir Immune Defic Syndr.
31. Barbour JD, Sauer MM, Sharp ER, Garrison KE, Long BR, et al. (2007) HIV-1/HSV-2 co-infected adults in early HIV-1 infection have elevated CD4+ T cell counts. PLoS ONE 2(10): e1080.
32. Koelle DM, Wald A (2000) Herpes simplex virus: The importance of asymptomatic shedding. J Antimicrob Chemother 45 Suppl T3: 1-8.
33. Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, et al. (2000) Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 342(12): 844-850.